.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Express Scripts
Chinese Patent Office
McKesson
Cantor Fitzgerald
McKinsey
Julphar
Covington
Accenture
Cerilliant

Generated: September 20, 2017

DrugPatentWatch Database Preview

ADRIAMYCIN PFS Drug Profile

« Back to Dashboard

What is the patent landscape for Adriamycin Pfs, and when can generic versions of Adriamycin Pfs launch?

Adriamycin Pfs is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in ADRIAMYCIN PFS is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.

Summary for Tradename: ADRIAMYCIN PFS

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list33
Clinical Trials: see list1,928
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADRIAMYCIN PFS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
ADRIAMYCIN PFS
doxorubicin hydrochloride
INJECTABLE;INJECTION063165-001Jan 30, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
ADRIAMYCIN PFS
doxorubicin hydrochloride
INJECTABLE;INJECTION063165-002Jan 30, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Baxter
Argus Health
Citi
McKinsey
QuintilesIMS
Mallinckrodt
Moodys
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot